UNEEG medical and King’s College London are awarded £1.8 million in the i4i Challenge Awards Call from the National Institute for Health and Care Research (NIHR) in the UK to conduct a multicentre, observational cohort study of the 24/7 EEG SubQ solution.
Read more about the study here.

UNEEG medical AT GmbH is established in Austria.

Our UNEEG™ MyConnect data-transfer solution is launched. With MyConnect, for the first time EEG data are automatically sent from the patient to the hospital.

UNEEG medical currently employs over 100 people in Denmark, Germany and the UK.

We move into new headquarters in Allerød, Denmark with our sister company T&W Engineering.

First US patient initiated in pivotal multi-centre study for US approval of 24/7 EEG SubQ solution. The study is conducted at the University of Pennsylvania (US), Mayo Clinic (US) and Freiburg University Hospital (Germany)

UNEEG medical DE GmbH is established in Germany.

UNEEG medical subsidiaries are established in the US and the UK.

The study “230 days of ultra long-term subcutaneous EEG: seizure cycle analysis and comparison to patient diary” is published – to date the longest case study involving subcutaneous EEG. The study shows that patient acceptability is high for the 24/7 EEG SubQ solution, with an average of 20.8 hours’ adherence per day in a real-life setting, and that sensitivity of review software UNEEG EpiSight is high. The study further identifies circadian and multidien seizure cycles.

Pivotal study “ultra long-term subcutaneous home monitoring of epilepsy - 490 days of EEG from nine patients” is published in Epilepsia. The study is the first real-life monitoring of EEG in people with epilepsy; study participants record EEG data in their home environment with the 24/7 EEG SubQ. The study demonstrates that objective, real-life electrographic seizure counting can be obtained from subcutaneous EEG recordings. The study further concludes a substantial difference between the patient’s self-reported seizure counts and the objective seizure counts recorded with our solution.

First UK patient implanted with the UNEEG SubQ as part of a USD 3 million programme funded by the Epilepsy Foundation of America as part of the project “My Seizure Gauge”.

We receive ethics approval to initiate an ultra long-term sleep monitoring trial under the heading “Sleep in the ultra long-term perspective: Seasonally and behaviourally induced variation”.

The 24/7 SubQ system is CE-marked, a major step forward in achieving our commercial ambitions.

UNEEG launches a strategic partnership with the Austrian Institute of Technology, which obtains a CE-mark on a specialized 2-channel version of their encevis software that includes an algorithm for seizure detection.

The study ”High similarity between EEG from subcutaneous and proximate scalp electrodes in patients with temporallobe epilepsy” is published, and shows that electrographic seizures can be monitored with the 24/7 SubQ.

Our ultra long-term EEG technology receives the prestigious Shark Tank Prize from the US Epilepsy Foundation of America. The prize is awarded to the most innovative idea that can help those living with epilepsy.

We change our name to UNEEG medical and introduce a new logo.
Around 20 people are now employed at the company.

Pilot study involving eight patients with diabetes is conducted at Odense University Hospital and Hillerød Hospital.

Pivotal paper ”EEG signal quality of a subcutaneous recording system compared to standard surface electrodes” shows that the signal quality of our implant at least equals that of scalp EEG.

The HypoSafe team and Widex EEG team are merged into a larger group, and are located at the Widex building in Lynge, Denmark.

Pilot study, involving 18 heathy subjects. The study is conducted at the Danish hospital Sydvestjysk sygehus.

First epilepsy PhD research project is initiated under the title “Detection and Prediction of Epileptic Seizures”.

Widex Holding becomes the majority shareholder of Hypo-Safe A/S. Widex Holding brings over 60 years’ experience in the design, manufacture and marketing of miniaturised medical devices to the company.

The company Hypo-Safe A/S is founded by Professor dr. med. Henning Beck-Nielsen and co-founder, engineer Rasmus Stig Jensen.

First clinical pilot trial is conducted in Denmark prior to the official founding of Hypo-Safe (the predecessor of UNEEG medical). Six people with diabetes are included. The company’s original aim was to develop an alert prior to severe hypoglycaemia for insulin-dependent diabetics based on the brain’s EEG signals.